Niquitin

Quick links to important sections

Niquitin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Niquitin

Property Description
Active ingredient Nicotine (e.g., Nicotine Polacrilex)
Forms Transdermal patch, lozenge, chewing gum, oral spray
Pharmacological class Nicotinic Acetylcholine Receptor (nAChR) Agonist
General purpose Management of nicotine dependence
Origin Synthetic alkaloid derivative

What Type of Medicine is Niquitin?

Niquitin is a specialized pharmaceutical preparation utilized as a Tobacco Cessation Aid and a core component of Nicotine Replacement Therapy (NRT). It is a single active agent product. Pharmacologically, it is classified as a Nicotinic Acetylcholine Receptor (nAChR) Agonist, which means the medicine directly engages the same receptors in the body that respond to nicotine.

As a treatment strategy for tobacco dependence, NRT is designed to increase the likelihood of successful cessation. Licensed forms of NRT provide pharmacological support intended to ease the transition to complete abstinence.


Composition and Physical Forms

The sole active ingredient in Niquitin is pharmaceutical-grade nicotine, often formulated as a resin complex such as Nicotine Polacrilex to ensure its stability and controlled release. The compound itself is considered synthetic for medicinal application, having been derived and purified from the naturally occurring tobacco alkaloid.

Niquitin is manufactured in diverse drug forms, including the transdermal patch (e.g., NiQuitin Clear), lozenge (e.g., NiQuitin Minis), chewing gum, and oral spray, each employing a distinct route of administration. The patch is designed for transdermal delivery, providing sustained delivery through the skin, while oral forms rely on buccal/oral mucosal absorption. This variety in delivery methods allows for different management strategies based on the chosen route of administration.


Niquitin's Role in Quitting Smoking

The preparation's general purpose is to facilitate smoking cessation by providing a reliable source of nicotine. This action directly addresses the physical symptoms of tobacco withdrawal, such as intense cravings and irritability. By managing the acute physical needs associated with nicotine dependence through controlled release, Niquitin allows the user to concentrate on the behavioral and psychological adjustments necessary for long-term freedom from tobacco.

What side effects are possible with Niquitin?

Possible side effects and safety information

The safety profile for Nicotine Replacement Therapy (NRT) products, such as Niquitin, is documented through regulatory sources (e.g., EMA and FDA) and categorized by the frequency and physiological system affected. Adverse reactions are grouped into System-Organ Classes (SOCs), including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Frequency-Classified Adverse Reactions

The incidence is formally classified, with many effects often associated with the body adjusting to cessation and nicotine delivery:

  • Very Common (ge 1/10): Headache, nausea, pruritus (itching, often with the patch), and throat irritation (with oral forms).
  • Common (ge 1/100 to <1/10): Dizziness, vomiting, dyspepsia, insomnia, abnormal dreams, and rash.
  • Uncommon (ge 1/1,000 to <1/100): Palpitations, tachycardia, hypertension, and hypersensitivity.
  • Rare (ge 1/10,000 to <1/1,000): Anaphylactic reaction and angioedema.
  • Frequency Not Known: Regulatory reports include Seizures.

Form- and Population-Specific Safety Notes

Adverse reactions specific to delivery forms include application site reactions (erythema, burning) for the patch, and mouth or throat irritation for the gum and lozenge. Many gastrointestinal and neurological effects are noted as being more common during the first few weeks of treatment.

Safety documents also specify caution for specific populations. Use requires particular consideration in patients with pre-existing conditions such as moderate to severe hepatic or renal impairment and those with recent myocardial infarction or unstable angina.

Overdose and Emergency Response

Nicotine overdose, the active component in Niquitin, is officially documented as presenting with a biphasic clinical course. Initial manifestations often involve stimulatory effects, including nausea, vomiting, dizziness, headache, excessive sweating, rapid heart rate (tachycardia), and high blood pressure. These symptoms signal the need for immediate action.

Larger exposures can progress to a severe depressant phase, which may lead to life-threatening systemic outcomes. These include critically low blood pressure (hypotension), slow heart rate (bradycardia), central nervous system depression, seizures, and respiratory failure, culminating in potential cardiovascular collapse or coma.

Official regulatory guidance mandates that immediate medical help must be sought for any suspected overdose. A user must stop use immediately upon experiencing initial symptoms like nausea or rapid heartbeat. For severe signs such as collapse, difficulty breathing, or seizures, emergency services must be contacted right away. Treatment is strictly supportive, as no specific antidote is known, and generally involves cardiorespiratory monitoring and symptomatic management. Any nicotine exposure in a child is classified as a medical emergency due to high susceptibility to toxicity.

Therapeutic Uses of Niquitin

What Niquitin Treats: Main Uses and Benefits

Niquitin is commonly used across conditions presenting with episodic or fluctuating manifestations related to nicotine dependence, and may be part of symptomatic management within supportive smoking cessation therapy.

This therapy is commonly used to help address the urge to smoke, and is considered relevant in clinical settings that involve acute or unstable symptom patterns. It is primarily applied in addressing the symptom domains of intense cravings, physical agitation and restlessness, and neuro-behavioral distress such as irritability and anxiety.

This supportive care is relevant in clinical settings that involve acute or unstable symptom patterns, such as a planned quit attempt or phases when symptoms become more noticeable. The core therapeutic benefit is to provide support that helps ease the overall symptom burden, allowing the individual to better focus on the required behavioral and psychological adjustments. The medication is relevant when short-term symptomatic assistance is needed to manage symptoms that interfere with daily functioning.


Quick Fact: Relief for Withdrawal Distress

Niquitin is commonly used to help with the full cluster of nicotine withdrawal symptoms, which includes physical discomfort and emotional instability, assisting with maintaining functional stability during the early stages of cessation.

Regulatory References

  1. US Department of Health and Human Services’ Smokefree.gov overview

Eligibility and Restrictions for Use

Who can and cannot use Niquitin?

The eligibility for Niquitin is strictly defined by regulatory guidelines. Standard use is allowed for adults aged 18 years and older who are dependent smokers actively seeking to quit.

The medicine is contraindicated and must not be used by non-smokers, occasional smokers, or children under 12 years of age. Use is also prohibited for individuals with a known hypersensitivity to nicotine or any component of the product.

Use is officially restricted or requires medical supervision for adolescents (12–17 years) and patients with certain medical conditions. This includes individuals with unstable cardiovascular conditions, such as a recent myocardial infarction or severe cardiac arrhythmias. Caution is also required for patients with uncontrolled hyperthyroidism, pheochromocytoma, or active gastrointestinal inflammation. Patients with moderate to severe hepatic or renal impairment must also use the product with caution.

Regarding physiological states, Niquitin is not approved for treating tobacco dependence during pregnancy before behavioral methods are attempted. During lactation, intermittent NRT forms are often preferred over the patch.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Niquitin (Nicotine Replacement Therapy), focusing strictly on information found in government regulatory documents.


Pharmacokinetic and Pharmacodynamic Effects

Type of Interaction Description and Mechanism
Cessation-Mediated Metabolic Shift The act of stopping smoking removes the potent inducing effect of tobacco smoke (not nicotine) on the CYP1A2 liver enzyme. This leads to a decrease in metabolism and a subsequent rise in the plasma concentrations of co-administered medicines that are CYP1A2 substrates.
Pharmacodynamic Counteraction Nicotine's systemic effects, such as the release of catecholamines, may counteract the desired therapeutic effects of certain agents, including Beta-adrenergic Blocking Agents.

Clinically Significant Interactions

  • Medicines Requiring Dose Monitoring: Because of the cessation-mediated metabolic shift, agents like Theophylline, Clozapine, Olanzapine, Fluvoxamine, and Warfarin require close clinical monitoring and potential dose adjustment upon commencing Niquitin therapy.
  • Insulin: Smoking cessation increases the absorption of subcutaneous insulin, which may necessitate a reduction in the insulin dose.

Product-Specific Constraints

For oral forms (gum, lozenge), consuming acidic beverages (e.g., coffee, juices) for 15 minutes before and during use must be avoided, as this may interfere with the buccal absorption of nicotine.

Population Considerations

The clearance of nicotine may be decreased in patients with moderate to severe hepatic impairment (liver dysfunction) or severe renal impairment (kidney dysfunction), which can increase the risk of systemic exposure.

Mechanism of Action

How Niquitin Works

The mechanism of action for Niquitin is defined by the pharmacodynamic role of its active component, nicotine, which acts directly upon nicotinic acetylcholine receptors (nAChRs) located primarily in the central nervous system (CNS). Nicotine functions as an agonist, binding to these receptors to initiate the specific molecular cascade associated with their activation.

The controlled delivery of nicotine from the drug formulation provides a sustained, non-pulsatile engagement of the nAChRs. This steady receptor occupation influences subsequent signal transduction cascades and neurotransmitter dynamics within defined neural pathways. By continuously modulating receptor activity, the mechanism supports the physiological adjustment of affected neural systems. This approach to mechanistic regulation contributes to a more regulated state within the targeted pathways following the cessation of external nicotine supply.

Dosage and Administration Information

How Nicotine Replacement Therapy (NRT) is Used

Administration of Niquitin, which delivers nicotine as part of a Nicotine Replacement Therapy (NRT) protocol, is based on standardized administration patterns.

Approved forms dictate the route of administration: the transdermal patch is applied to the skin (topical administration), while the lozenge and chewing gum rely on buccal/oromucosal absorption.


Labeled Dosing Regimens and Schedule

Dosage selection is stratified based on the individual's baseline smoking habits. For instance, the transdermal patch regimen for those smoking more than 10 cigarettes daily typically starts with 21 mg/24 hours, followed by a step-down schedule to 14 mg and then 7 mg over a total course of up to 10 weeks. The lozenge dose is determined by the time to first cigarette after waking.

Administration Pattern Frequency and Duration (Typical)
Patch One patch every 24 hours, with strength reduced over 8 to 10 weeks.
Lozenge/Gum Used on a scheduled/as-needed basis, tapering from every 1 to 2 hours to every 4 to 8 hours over a total 12-week period.

Specific Administration Requirements

Proper use requires adherence to product-specific instructions. The patch site must be rotated daily and applied to clean, dry, non-hairy skin; do not cut the patch. Oral forms, such as the lozenge and gum, must be administered under conditions that support absorption: do not eat or drink 15 minutes before or during use to avoid interference from acidic beverages. The total duration of NRT is designed to guide the user towards completion of the tapering process by 12 weeks.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical evidence for nicotine replacement therapy (NRT), including transdermal patches and oral formats like lozenges, supports its use in smoking cessation. These products temporarily replace nicotine to reduce the severity of withdrawal symptoms and cravings associated with quitting tobacco use.

Efficacy and Abstinence Rates

  • Overall Effectiveness: Meta-analyses of randomized controlled trials (RCTs) indicate that all commercially available forms of NRT, when compared to a control or placebo, increase the likelihood of achieving sustained abstinence (quitting for six months or longer) by approximately 50% to 70%.
  • Dose Response: Some research has explored whether higher doses of nicotine patches may be associated with small increases in quit rates compared to standard doses, particularly for individuals with higher nicotine dependence.
  • Combination Therapy: Studies have examined the benefit of combining two forms of NRT (e.g., a transdermal patch for steady nicotine delivery and an oral format for acute cravings). Limited evidence suggests that this combination may lead to numerically higher quit rates compared to using a single NRT format alone.

Safety and Special Populations

Clinical trials consistently report that NRT products are generally well-tolerated. Common, typically mild adverse events are often localized to the delivery method (e.g., skin irritation from patches, or mouth/throat irritation from lozenges or gums).

  • Cardiovascular Safety: Studies have generally found no clear evidence that NRT increases the risk of serious cardiovascular events, such as heart attacks, in individuals using the products for smoking cessation.
  • Pregnancy: Evidence regarding the effectiveness and safety of NRT use during pregnancy remains limited. Health guidelines emphasize behavioral support as the primary approach, with NRT considered on a case-by-case basis when behavioral interventions alone are insufficient.

Frequently Asked Questions (FAQ)

Common questions about Niquitin (FAQ)

Q: Is Niquitin available over the counter?

A: According to regulatory documents, Nicotine Replacement Therapy (NRT) products like Niquitin are generally approved as over-the-counter (OTC) aids for smoking cessation. This classification means the products can typically be purchased without a prescription to help manage nicotine dependence.

Q: Why do some people prefer Niquitin patches over gums?

A: Official information indicates that the choice between patches and gum often relates to their different delivery methods. Patches provide a continuous, steady release of nicotine, while gum and lozenges allow for acute, on-demand use to manage sudden cravings. This difference provides flexibility based on an individual's cessation strategy.

Q: Can Niquitin be used by people with a history of heart problems?

A: Regulatory guidance specifies that Niquitin is to be used with caution or under medical supervision by patients with certain cardiovascular conditions. These include a recent heart attack (myocardial infarction), unstable angina (chest pain), or uncontrolled high blood pressure (hypertension). The product labels describe the conditions under which its use is restricted.

Q: Does Niquitin interact with caffeine consumption?

A: Official administration instructions state that for oral forms of Niquitin, the consumption of acidic beverages (such as coffee, tea, or fruit juices) is to be avoided. Consuming these drinks for 15 minutes before or during use may interfere with the buccal absorption of nicotine through the mouth lining.

Q: Is Niquitin safe for women who are planning to become pregnant?

A: Regulatory guidance emphasizes that, ideally, quitting smoking during pregnancy should be achieved without pharmaceutical support. Official information indicates that NRT use is typically considered only after attempting behavioral methods and under the supervision of a healthcare professional. This approach is designed to follow established safety protocols.

Q: Can Niquitin affect my blood pressure?

A: Official product information lists hypertension (high blood pressure) as an uncommon adverse reaction to Niquitin. Nicotine is a compound that can cause a temporary increase in blood pressure and heart rate. This is noted as a potential effect documented in regulatory materials.

Q: What is the general profile of a person described as an 'appropriate' user of Niquitin?

A: Niquitin is indicated for use by adults aged 18 years and older who are dependent smokers and are actively seeking to quit or reduce their smoking. Conversely, it is strictly contraindicated for non-smokers or occasional smokers.

Q: What is the relationship between the nicotine dose and the user's history of smoking?

A: The initial dose of Nicotine Replacement Therapy is typically stratified based on an individual's baseline smoking habits. Official dosing schedules often differentiate based on factors such as the number of cigarettes smoked daily or the time elapsed until the first cigarette after waking.

Q: What is the official definition of a 'serious' side effect for Niquitin?

A: Regulatory documents classify side effects by their frequency and type. While a specific, plain-language definition of 'serious' is not provided, the rarest and most severe effects reported include anaphylactic reaction (a severe allergic reaction), angioedema (swelling beneath the skin), and seizures.

Q: What should I do if I accidentally swallow a piece of Niquitin gum?

A: Nicotine is considered toxic if consumed in high amounts, especially by children. Official guidance states that due to the risk of nicotine poisoning, if the product is accidentally swallowed, immediate medical attention should be sought and the Poison Control Center contacted immediately.

Q: What are some common misunderstandings about how to use Niquitin?

A: Official directions describe several practices that are to be avoided for proper use. These include eating or drinking acidic beverages too close to the use of oral forms. For the patch, official instructions state the product is not to be cut, and the application site should be rotated.

Q: Are there special considerations for using Niquitin if you have diabetes?

A: Caution is advised when Niquitin is used by patients with insulin-dependent diabetes. Official information indicates that the act of smoking cessation may increase the absorption of subcutaneous insulin in the body, which might necessitate an adjustment to the insulin dose.

Q: What happens if you use Niquitin and still smoke a cigarette?

A: Niquitin is intended to be used as a replacement for nicotine from cigarettes. Using Niquitin while also smoking may lead to an increased total intake of nicotine, which can elevate the risk of experiencing nicotine-related adverse effects or symptoms of nicotine overdose.

Q: Why is it described that Niquitin should be used for a set period of time?

A: The treatment regimen is designed for a set duration, typically involving a step-down schedule over 8–12 weeks. This systematic tapering is designed to guide the user toward the ultimate goal of complete cessation of nicotine use and help avoid potential long-term dependence on the NRT product itself.

Q: Do any official sources mention specific dietary restrictions while using Niquitin?

A: Regulatory documents specify one key constraint: for oral forms (gum, lozenge), the consumption of acidic beverages (e.g., coffee, juice) is to be avoided 15 minutes before and during use. No other broad dietary restrictions are generally listed in official documentation.

Q: Is Niquitin use permitted for people who have certain skin conditions?

A: Official guidance indicates that if a severe or persistent local reaction at the patch application site (such as severe itching or swelling) or a generalized skin reaction develops, the product's use is often discontinued. This is noted as a specific safety protocol.

Q: What are the concerns about using Niquitin with prescription medications for anxiety?

A: The cessation of smoking can cause a metabolic shift (reduced enzyme activity) in the body, which may increase the concentration of certain medicines. The interaction section of official labels lists some prescription drugs, such as Fluvoxamine (used for anxiety/OCD), as being affected by this shift.

Q: Can Niquitin be used by non-smokers who are around secondhand smoke?

A: Niquitin is officially contraindicated for individuals who are non-smokers and is therefore not to be used by them. The product is intended only for individuals who are dependent smokers actively pursuing smoking cessation.

Q: What is the main function of the other ingredients in Niquitin besides nicotine?

A: In addition to the active nicotine component, Niquitin contains excipients—or inactive ingredients—that serve a functional role. For instance, in the patch, these ingredients form the rate-controlling membrane or contact adhesive designed to support the controlled release and delivery of nicotine into the body.

Q: Does Niquitin interact with alcohol?

A: For oral forms (gum, lozenge), consumption of any beverage, including alcoholic drinks, is to be avoided for 15 minutes before and during use. This is a specific administration constraint intended to prevent interference with the buccal absorption of nicotine.

Q: Is Niquitin mentioned in any major public health guidelines?

A: Yes, Nicotine Replacement Therapy (NRT) is widely recognized. It is included on the WHO Essential Medicines List (EML), and major health guidelines describe that NRT has been shown to increase the likelihood of successfully quitting compared to quitting by willpower alone.

Q: Does Niquitin have an expiry date, and what happens if it's past it?

A: As with other medicines, Niquitin has an expiry date listed on the packaging. Regulatory bodies indicate that the product should not be used past this date due to potential concerns regarding the medication's intended potency and efficacy over time.

Q: Are there any known interactions between Niquitin and common cold medicines?

A: Nicotine replacement can cause a metabolic shift which may affect the concentration of certain prescription drugs. Specific common cold medicines are not typically listed in regulatory documents, but users should be aware of the general metabolic shift described in the interactions section.

Q: What are the requirements for research evidence cited by regulatory bodies for Niquitin?

A: Regulatory approval is based on a rigorous evaluation of scientific evidence. This evidence primarily requires Randomized Controlled Trials (RCTs) and meta-analyses to demonstrate that the product's benefits for smoking cessation outweigh any identified risks.

Q: Can Niquitin be used for a short-term need, or only for a full program?

A: While Niquitin is indicated for use as part of a full smoking cessation program involving a tapering schedule, official guidance notes it may also be used to manage acute cravings during periods of temporary abstinence from smoking.

Q: What is the official description of the feeling of 'nicotine craving' that Niquitin addresses?

A: Official documentation describes Niquitin's purpose as relieving and/or preventing the craving and other nicotine withdrawal symptoms associated with tobacco dependence. This is the therapeutic goal of Nicotine Replacement Therapy.

Q: What evidence exists regarding Niquitin's use in individuals with respiratory conditions?

A: Caution is advised for patients with certain pre-existing conditions. Official labels do not list common respiratory conditions as a contraindication for all NRT forms, but some oral forms may cause temporary throat or mouth irritation. The product is intended for use in smoking cessation.

How should Niquitin be stored and disposed of?

How to Store and Dispose of Nicotine (Niquitin)


Storage Requirements

Nicotine replacement products must be stored at controlled room temperature, typically between 20 C and 25 C. The product must be protected from light and moisture and must not be frozen or refrigerated. It should be kept in its original container and individual sealed pouches until immediately before use.

Child-Safety and Disposal

Due to the risk of serious nicotine poisoning, all products must be stored out of the sight and reach of children and pets. Used patches retain a hazardous amount of nicotine; they must be folded sticky sides together and placed back into the original pouch before being discarded. Unused, expired, or waste products must be disposed of in accordance with local regulations and should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Niquitin found in:

A-Z Index: